机构:
Mem Sloan Kettering Canc Ctr, Div Surg Oncol, Dept Surg, New York, NY 10065 USAMem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USA
Crago, Aimee M.
[2
]
Azu, Michelle
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USAMem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USA
Azu, Michelle
[1
]
Tierney, Shannon
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USAMem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USA
Tierney, Shannon
[1
]
Morrow, Monica
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USAMem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USA
Morrow, Monica
[1
]
机构:
[1] Mem Sloan Kettering Canc Ctr, Div Breast Surg, Dept Surg, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Div Surg Oncol, Dept Surg, New York, NY 10065 USA
Breast cancer;
Randomized clinical trials;
Literature review;
Breast-conserving therapy;
SURGICAL ADJUVANT BREAST;
CARCINOMA-IN-SITU;
20-YEAR FOLLOW-UP;
LYMPH-NODE DISSECTION;
POSTMENOPAUSAL WOMEN;
POSTOPERATIVE RADIOTHERAPY;
PREOPERATIVE CHEMOTHERAPY;
EUROPEAN ORGANIZATION;
RADICAL-MASTECTOMY;
TAMOXIFEN THERAPY;
D O I:
10.1016/j.soc.2009.09.003
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Breast cancer remains the most common cancer diagnosed in women and the second leading cause of cancer-related deaths in this group. Significant advances in the treatment of breast cancer and in the ability to screen for the disease mean that it is also one of the most curable forms of cancer. Long-term updates of the trials reviewed in the previous edition of this article have demonstrated that breast-conserving therapy remains a viable option for most patients, and that local control is related to overall survival. New chemotherapeutic options and endocrine therapies are available to select subsets of patients, and the use of endocrine therapy in breast cancer prevention has been shown to be of clear benefit. The sheer number of breast cancer-related randomized, controlled trials makes it impossible to review all level la evidence in this article but, where possible, extensive referencing and tabular review of related trials are used to provide the reader with a clear outline of the central data dictating current standard of care.